Tag Archives | CRPC

Zytiga (abiraterone acetate) price will impact the Prostate Cancer market following FDA approval

Sally Church on Pharma Strategy Blog has written about the FDA approval yesterday of Ortho Biotech’s ($JNJ) abiraterone acetate, brand name Zytiga for the treatment of castration resistant prostate cancer in patients who have received prior chemotherapy with docetaxel. The final data showed a 4.6 month increase in overall survival (OS) in these very sick […]

Continue Reading

Abiraterone acetate in advanced prostate cancer

As many of you know, Sally Church attended the recent European Association of Urology Congress in Vienna. In the first video blog post that she’s ever done on Pharma Strategy Blog, she shares her impressions of the meeting and the changing landscape in advanced prostate cancer.  One of the key new product approvals expected this […]

Continue Reading

2010 was a Grand Cru for Advanced Prostate Cancer Drugs

Many European doctors enjoy a glass of good wine, so Bertrand Tombal’s metaphor that 2010 was a great year for advanced prostate cancer drugs was well received at the recent European Association of Urology Congress in Vienna. Sally Church attended the meeting, and shared her thoughts on “the changing face of advanced prostate cancer” in […]

Continue Reading